-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The approved systemic therapy for advanced gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs) has shown limited ability to reduce tumor burden, and has no anti-tumor activity after being developed into targeted drugs (TA).
This study aims to evaluate the efficacy and safety of lenvatinib in patients with advanced GEP-NETs who have been previously treated .
To evaluate the efficacy and safety of lenvatinib in patients with advanced GEP-NETs who have previously been treated
This is a multi-center, single-arm, open-label Phase II clinical trial, divided into two parallel cohorts, involving 21 units in 4 European countries.
From September 2015 to March 2017, 111 patients were recruited, including 55 panNET patients and 56 GI-NET patients.
Treatment remission
Treatment remissionAfter a median follow-up of 23 months, the overall response rate was 29.
After a median follow-up of 23 months, the overall response rate was 29.
PFS rate: A picture panNET, B picture GI-NET
PFS rate: A picture panNET, B picture GI-NETThe most common adverse events were fatigue, hypertension and diarrhea; 93.
93.
Levatinib has a certain effect in NET patients who have progressed after other TA treatments, suggesting that levatinib may be used for the treatment of advanced GEP-NET levatinib has a certain effect in NET patients who have progressed after other TA treatments , Suggesting that lenvatinib may be used to treat advanced GEP-NET
Original source:
Original source:Jaume Capdevila, et al.
org/doi/full/10.
1200/JCO.
20.
03368">Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
in this message
